What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Moshe Talpaz spends much of his time researching Internal medicine, Chronic myelogenous leukemia, Immunology, Gastroenterology and Imatinib mesylate.
His Internal medicine research integrates issues from Surgery, Philadelphia chromosome and Oncology.
The Chronic myelogenous leukemia study combines topics in areas such as Salvage therapy, Alpha interferon, Bone marrow and Transplantation.
His Immunology study frequently links to related topics such as Clinical significance.
His Gastroenterology study integrates concerns from other disciplines, such as Combination chemotherapy, Chemotherapy, Hematologic Response, Pathology and Toxicity.
Moshe Talpaz has included themes like Growth factor receptor and Drug resistance in his Imatinib mesylate study.
His most cited work include:
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome (2465 citations)
- Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia (1808 citations)
- Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias (1448 citations)
What are the main themes of his work throughout his whole career to date?
Moshe Talpaz mainly investigates Internal medicine, Chronic myelogenous leukemia, Immunology, Cancer research and Gastroenterology.
Moshe Talpaz combines subjects such as Surgery and Oncology with his study of Internal medicine.
His Chronic myelogenous leukemia research is multidisciplinary, incorporating perspectives in Chemotherapy, Alpha interferon, Philadelphia chromosome, breakpoint cluster region and Bone marrow.
His Immunology study combines topics in areas such as Cancer and Haematopoiesis.
His research in Cancer research intersects with topics in Tyrosine kinase, ABL, K562 cells and Tyrosine-kinase inhibitor.
His work in Gastroenterology tackles topics such as Adverse effect which are related to areas like Discontinuation.
He most often published in these fields:
- Internal medicine (50.64%)
- Chronic myelogenous leukemia (31.25%)
- Immunology (28.44%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (50.64%)
- Myelofibrosis (12.37%)
- Oncology (19.39%)
In recent papers he was focusing on the following fields of study:
Moshe Talpaz mainly focuses on Internal medicine, Myelofibrosis, Oncology, In patient and Cancer research.
His research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with issues in Tolerability.
The concepts of his Myelofibrosis study are interwoven with issues in Clinical trial and Cohort.
His Oncology research incorporates elements of Relapsed refractory, Refractory, Nilotinib and Transplantation.
His studies deal with areas such as Apoptosis, Cell culture, Gene knockdown and Cancer as well as Cancer research.
His Myeloid leukemia research is multidisciplinary, relying on both Tyrosine kinase, Leukemia, Philadelphia chromosome and Tyrosine-kinase inhibitor.
Between 2013 and 2021, his most popular works were:
- Integrative clinical genomics of metastatic cancer (355 citations)
- Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth (223 citations)
- Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo. (182 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Moshe Talpaz mostly deals with Internal medicine, Adverse effect, Myelofibrosis, Oncology and Cancer research.
His Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
Myeloid leukemia is the focus of his Cancer research research.
His biological study spans a wide range of topics, including Tyrosine kinase, Philadelphia chromosome, Tyrosine-kinase inhibitor, Leukemia and Protein kinase domain.
His Philadelphia Chromosome Positive research incorporates elements of Nuclear medicine and Immunology.
His work on Imatinib mesylate as part of general Imatinib research is frequently linked to EPIC, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
